6-bromo-N-phenethylquinazolin-4-amine | 307538-36-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-bromo-N-phenethylquinazolin-4-amine
• 英文别名: 6-bromo-N-(2-phenylethyl)quinazolin-4-amine
• CAS: 307538-36-9
• 化学式: C₁₆H₁₄BrN₃
• 分子量: 328.211
• InChiKey: GFAXHVDRUDGRNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-bromo-N-phenethylquinazolin-4-amine 、 3-甲酰基苯硼酸 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以40%的产率得到
  参考文献：
  名称：

  Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof

  摘要：

  根据公式I的4-氨基喹唑啉化合物替代物，其生产方法，含有这些化合物的药物组合物以及用于治疗或抑制疾病状态或疾病状态的用途。

  公开号：

  US20090069320A1
• 作为产物：
  描述：

  6-溴-4-氯喹唑啉 、 苄胺 在 吡啶 作用下， 以 乙醇 为溶剂， 生成 6-bromo-N-phenethylquinazolin-4-amine
  参考文献：
  名称：

  Potent inhibitors of Huntingtin protein aggregation in a cell-based assay

  摘要：

  A quinazoline that decreases polyglutamine aggregate burden in a cell-based assay was identified from a high-throughput screen of a chemical-compound library, provided by the NIH Molecular Libraries Small Molecule Repository (MLSMR). A structure and activity study yielded leads with submicromolar potency. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.087

文献信息

• Identification of CDKI pathway inhibitors
  申请人：Chang Bey-Dih

  公开号：US20080033000A1

  公开（公告）日：2008-02-07

  The invention relates to the inhibition of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.
• CDKI PATHWAY INHIBITORS AND USES THEREOF
  申请人：Chang Bey-Dih

  公开号：US20090281129A1

  公开（公告）日：2009-11-12

  The invention relates to the inhibition of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.
• CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein
  申请人：Porter Donald

  公开号：US20100190807A1

  公开（公告）日：2010-07-29

  The invention relates to the inhibition of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to methods for inhibiting increases in MAPT expression induced by the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.